Abstract
Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63.
Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.
Erratum For:
Low doses of CPS49 and flavopiridol combination as potential treatment for advanced
prostate cancer
Current Pharmaceutical Biotechnology
Title:Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Volume: 20 Issue: 12
Author(s): Florencia Zalazar, Paola De Luca, Kevin Gardner, William D. Figg, Roberto Meiss, Raúl G. Spallanzani, Pablo Vallecorsa, Belén Elguero, Javier Cotignola, Elba Vazquez and Adriana De Siervi*
Affiliation:
- Laboratorio de Oncologia Molecular y Nuevos Blancos Terapeuticos, Instituto de Biologia y Medicina Experimental (IBYME-CONICET), Buenos Aires,Argentina
Abstract:
Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63.
Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.
Export Options
About this article
Cite this article as:
Zalazar Florencia , Luca De Paola , Gardner Kevin , Figg D. William, Meiss Roberto , Spallanzani G. Raúl , Vallecorsa Pablo , Elguero Belén , Cotignola Javier , Vazquez Elba and Siervi De Adriana*, Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer, Current Pharmaceutical Biotechnology 2019; 20 (12) . https://dx.doi.org/10.2174/138920102012190919103433
DOI https://dx.doi.org/10.2174/138920102012190919103433 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Patent Selections
Recent Patents on Food, Nutrition & Agriculture Leukocyte-Independent Effects of CC-Chemokines on Vascular Remodeling
Current Pharmaceutical Biotechnology Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Data Integration in Functional Analysis of MicroRNAs
Current Bioinformatics Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Small Molecules and Future Regenerative Medicine
Current Topics in Medicinal Chemistry Somatostatin and its Analogs
Current Drug Targets Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Prediction of Biological Activity Spectra for Substances: Evaluation on the Diverse Sets of Drug-Like Structures
Current Medicinal Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Conserved Domains, Residues, WebLogo and Active Sites of Caspase- Cascades Related to Apoptotic Signaling Pathway
Current Bioinformatics Neuroimmunomodulation and Aging: A Role for Transferrin and the Hypothalamus/Thymus Axis
Current Aging Science Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Current Pharmaceutical Design Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Current Pharmaceutical Design